Bictegravir
Bictegravir (INN; BIC, formerly known as GS-9883) is an antiviral drug of the integrase inhibitor class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences; in vitro and clinical results were presented by Gilead in the summer of 2016. In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection and the combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.
Wikipage redirect
primaryTopic
Bictegravir
Bictegravir (INN; BIC, formerly known as GS-9883) is an antiviral drug of the integrase inhibitor class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences; in vitro and clinical results were presented by Gilead in the summer of 2016. In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emtricitabine (FTC) for the treatment of HIV-1 infection and the combination drug bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) was approved for use in the United States in 2018.
has abstract
Bictegravir (INN; BIC, formerl ...... in the United States in 2018.
@en
CAS number
1611493-60-7
ChEBI
DrugBank
FDA UNII code
8GB79LOJ07
KEGG
PubChem
Link from a Wikipage to an external page
Wikipage page ID
52,935,102
page length (characters) of wiki page
Wikipage revision ID
1,024,340,647
Link from a Wikipage to another Wikipage
CAS number
ChEBI
ChemSpiderID
44,208,822
DrugBank
DB11799
@en
IUPAC name
KEGG
D10909
@en
PubChem
90,311,989
SMILES
c1cF
@en
StdInChIKey
SOLUWJRYJLAZCX-LYOVBCGYSA-N
@en
wikiPageUsesTemplate
subject
comment
Bictegravir (INN; BIC, formerl ...... in the United States in 2018.
@en
label
Bictegravir
@en